ERCI is pleased to announce that the presentations from the 2nd Meeting of the European Research Consortium on ITP, held in Paris on April 23–24, 2026, are now available online.
The meeting brought together approximately 250 participants from across Europe and beyond, confirming the growing interest in collaborative research and clinical innovation in immune thrombocytopenia (ITP). Over two days, international experts discussed the latest advances in ITP biology, diagnosis, registries, treatment strategies, guidelines, pediatric ITP, quality of life, and artificial intelligence applications in the field.
The attached PDF gathers the presentations delivered during the scientific sessions, offering participants and colleagues the opportunity to revisit key discussions, insights, and latest developments shared during the meeting.
We would like to thank all speakers, participants, sponsors, and organizing staff for contributing to the success of the meeting and for fostering collaboration within the international ITP community.
We look forward to continuing these scientific exchanges through future ERCI initiatives and meetings.
SESSION 1: NEW INSIGHTS IN THE BIOLOGY AND DIAGNOSIS OF ITP
Chairs: M. Michel, F. Zaja
The role of platelets in innate and adaptive immunity
J.W. Semple
Predictive markers of treatment response: where do we stand?
E. Lucchini
SESSION 2: GUIDELINES, DEFINITIONS AND REGISTRIES
Chairs: M.L. Lozano, G. Moulis
The new EHA guidelines: current status
M. Csenar, W. Ghanima
Why registries are useful: advances and gaps
G. Moulis
SESSION 3: ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 1)
Chairs: T.J. González-López, T. Kühne
Inhibiting Syk in ITP
T.J. González-López
How BTK inhibitors may change the therapeutic approach in ITP
N. Cooper – TBA
SESSION 3 ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 2)
Chairs: M. Michel, F. Rodeghiero
Anti-CD38 monoclonal antibodies in ITP: current status
W. Ghanima
Targeting BAFF/BAFF-R in ITP
F. Zaja
Bispecific antibodies and CAR-T cells: do they have a place in ITP?
K. Trautman-Grill
Other novel therapeutic approaches (C1 inhibition, FcRn inhibition)
S. Audia
SESSION 4: ITP IN SPECIFIC SITUATIONS
Chairs: B. Godeau, F. Rodeghiero
What’s new in childhood / AYA ITP?
T. Kühne, A. Schifferli
ITP during pregnancy: lessons from the last 5 years
J.B. Bussel
Pharmacoeconomics of ITP: does cost matter?
B. Godeau
SESSION 5: QUALITY OF LIFE, ARTIFICIAL INTELLIGENCE, SECONDARY ITP
Chairs: W. Ghanima, M.L. Lozano
Quality of life in ITP
A. Hart
What AI can bring to ITP
A.B. Provan
Management of secondary ITP: what differs from primary ITP?
M. Mahévas
SESSION 6: ABSTRACT PRESENTATIONS
N. Cooper, D. Provan
OC2. Circulating CD8 T cells as a potential biomarker of non-response to rituximab in ITP
R. Praliaud
OC3. Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections
E. Han
OC4. Generation of synthetic patients in immune thrombocytopenia: experience from the Italian GIMEMA ITP0918 (Immune Thrombocytopenia) registry
G. Marsili
OC6. BCMA (B-Cell Maturation Antigen)-targeting t-cell-engager therapy induces sustained remission in immune thrombocytopenia
M.L. Hütter-Krönke